Iltamiocel is an investigational autologous cell therapy for stress urinary incontinence, showing promise in previous trials and receiving FDA designation. The CELLEBRATE trial involves 96 ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk ...

Nearly 60% of patients taking vibegron remained on treatment at 1 year. The real-world, phase 4 COMPOSUR study (NCT05067478) found that nearly 60% of patients taking vibegron remained on treatment at ...

Paul E. Dato, MD, discusses how formulation and dosing differences between abiraterone options affect absorption and tolerability, with the micronized version potentially providing better compliance ...

Paul E. Dato, MD, discusses how the presence of a BRCA mutation can influence treatment selection and sequencing, supporting consideration of upfront triplet therapy intensification and planning for ...

Telemedicine has expanded access to urologic oncology care, especially during the COVID-19 pandemic, by enabling remote consultations and treatments. Legislative advancements have supported telehealth ...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Alex Tatem, MD, a urologist with Urology of Indiana and corporate director of men’s health for US Urology Partners, for ...

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD. “The challenge is, from a statistical study design ...

Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to ...

Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual ...

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial ...